Healthdirect Free Australian health advice you can count on.
Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately
healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.
NSW Health Alert: Any patients who have received dental treatment from Mr Safuan (Steven) Hasic at 70 Victoria Ave, Mortdale NSW 2223 may
be at risk of blood-borne viruses and should see their GP for precautionary testing. More information is available from
NSW Health
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
NON-HODGKINS LYMPHOMA (NHL)
RIXIMYO® (rituximab) is indicated for treatment of patients with:
CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma,
CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma,
CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy.
CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
RIXIMYO® (rituximab) is indicated for the treatment of patients with CD20 positive chronic lymphocytic
leukaemia in combination with chemotherapy.
RHEUMATOID ARTHRITIS (RA)
RIXIMYO® (rituximab) in combination with methotrexate is indicated for the treatment of adult
patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance
to at least one tumour necrosis factor (TNF) inhibitor therapy.
Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray
when given in combination with methotrexate.
GRANULOMATOSIS WITH POLYANGIITIS (WEGENERS) (GPA) AND MICROSCOPIC
POLYANGIITIS(MPA)
RIXIMYO® (rituximab) in combination with glucocorticoids is indicated for the induction of remission
in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners
granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with
rituximab have not been established.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on October, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
NON-HODGKINS LYMPHOMA (NHL)
RIXIMYO® (rituximab) is indicated for treatment of patients with:
CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma,
CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma,
CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy.
CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
RIXIMYO® (rituximab) is indicated for the treatment of patients with CD20 positive chronic lymphocytic
leukaemia in combination with chemotherapy.
RHEUMATOID ARTHRITIS (RA)
RIXIMYO® (rituximab) in combination with methotrexate is indicated for the treatment of adult
patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance
to at least one tumour necrosis factor (TNF) inhibitor therapy.
Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray
when given in combination with methotrexate.
GRANULOMATOSIS WITH POLYANGIITIS (WEGENERS) (GPA) AND MICROSCOPIC
POLYANGIITIS(MPA)
RIXIMYO® (rituximab) in combination with glucocorticoids is indicated for the induction of remission
in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners
granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with
rituximab have not been established.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
NON-HODGKINS LYMPHOMA (NHL)
RIXIMYO® (rituximab) is indicated for treatment of patients with:
CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma,
CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma,
CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy.
CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
RIXIMYO® (rituximab) is indicated for the treatment of patients with CD20 positive chronic lymphocytic
leukaemia in combination with chemotherapy.
RHEUMATOID ARTHRITIS (RA)
RIXIMYO® (rituximab) in combination with methotrexate is indicated for the treatment of adult
patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance
to at least one tumour necrosis factor (TNF) inhibitor therapy.
Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray
when given in combination with methotrexate.
GRANULOMATOSIS WITH POLYANGIITIS (WEGENERS) (GPA) AND MICROSCOPIC
POLYANGIITIS(MPA)
RIXIMYO® (rituximab) in combination with glucocorticoids is indicated for the induction of remission
in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners
granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with
rituximab have not been established.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on October, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
NON-HODGKINS LYMPHOMA (NHL)
RIXIMYO® (rituximab) is indicated for treatment of patients with:
CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma,
CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma,
CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy.
CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
RIXIMYO® (rituximab) is indicated for the treatment of patients with CD20 positive chronic lymphocytic
leukaemia in combination with chemotherapy.
RHEUMATOID ARTHRITIS (RA)
RIXIMYO® (rituximab) in combination with methotrexate is indicated for the treatment of adult
patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance
to at least one tumour necrosis factor (TNF) inhibitor therapy.
Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray
when given in combination with methotrexate.
GRANULOMATOSIS WITH POLYANGIITIS (WEGENERS) (GPA) AND MICROSCOPIC
POLYANGIITIS(MPA)
RIXIMYO® (rituximab) in combination with glucocorticoids is indicated for the induction of remission
in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners
granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with
rituximab have not been established.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
